XERIJECT Trademark

Trademark Overview

On Friday, December 4, 2020, a trademark application was filed for XERIJECT with the United States Patent and Trademark Office. The USPTO has given the XERIJECT trademark a serial number of 90980394. The federal status of this trademark filing is REGISTERED as of Tuesday, October 17, 2023. This trademark is owned by Xeris Pharmaceuticals, Inc.. The XERIJECT trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development; pharmaceutical drug formulation and development services; providing information on drug technology platforms for the formulation and development of drugs and biologics
xeriject

General Information

Serial Number90980394
Word MarkXERIJECT
Filing DateFriday, December 4, 2020
Status700 - REGISTERED
Status DateTuesday, October 17, 2023
Registration Number7197021
Registration DateTuesday, October 17, 2023
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 29, 2021

Trademark Statements

Goods and ServicesPharmaceutical research and development; pharmaceutical drug formulation and development services; providing information on drug technology platforms for the formulation and development of drugs and biologics

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, February 10, 2021
Primary Code042
First Use Anywhere DateFriday, November 30, 2018
First Use In Commerce DateFriday, November 30, 2018

Trademark Owner History

Party NameXeris Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressChicago, IL 60601
Party NameXeris Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressChicago, IL 60601
Party NameXeris Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressChicago, IL 60601

Trademark Events

Event DateEvent Description
Wednesday, February 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 8, 2020NEW APPLICATION ENTERED
Wednesday, May 12, 2021ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, May 26, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, May 24, 2021ASSIGNED TO EXAMINER
Wednesday, May 26, 2021EXAMINERS AMENDMENT -WRITTEN
Wednesday, May 26, 2021EXAMINER'S AMENDMENT ENTERED
Wednesday, May 26, 2021EXAMINERS AMENDMENT E-MAILED
Wednesday, May 26, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 9, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 29, 2021PUBLISHED FOR OPPOSITION
Tuesday, June 29, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 24, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, December 16, 2021SOU TEAS EXTENSION RECEIVED
Thursday, December 16, 2021SOU EXTENSION 1 FILED
Thursday, December 16, 2021SOU EXTENSION 1 GRANTED
Saturday, December 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 19, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Friday, May 27, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, May 31, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 27, 2022SOU EXTENSION 2 FILED
Friday, May 27, 2022SOU EXTENSION 2 GRANTED
Tuesday, January 31, 2023SOU EXTENSION 3 GRANTED
Thursday, June 23, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Tuesday, January 31, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, January 31, 2023SOU EXTENSION 3 FILED
Thursday, February 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 24, 2023DIVISIONAL REQUEST RECEIVED
Thursday, August 24, 2023USE AMENDMENT FILED
Thursday, August 24, 2023TEAS STATEMENT OF USE RECEIVED
Thursday, August 24, 2023TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, August 30, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 12, 2023DIVISIONAL PROCESSING COMPLETE
Tuesday, September 12, 2023STATEMENT OF USE PROCESSING COMPLETE
Wednesday, September 13, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, September 14, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, October 17, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, October 17, 2023REGISTERED-PRINCIPAL REGISTER

Related Keywords

xeriject development pharmaceutical formulation drug platforms drugs biologics technology services research